Epirubicin/taxane combinations in breast cancer: Experience from several Italian trials

Pierfranco Conte, Alessandra Gennari, Valentina Guarneri, Elisabetta Landucci, Sara Donati, Barbara Salvadori, Carmelo Bengala, Cimzia Orlandini, Editta Baldini

Research output: Contribution to journalArticle

Abstract

Doxorubicinlpaclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing doxorubicin with epirubicin (Ellence), a less cardiotoxic analog, produced an objective response rate of 84%, but with a low rate of cardiotoxicity. A careful cardiac monitoring in more than 100 patients treated with this combination has demonstrated that the risk of congestive heart failure is below 10% up to a cumulative epirubicin dose of 990 mg/m2. To examine the possibility that the pharmacokinetic and pharmacodynamic interactions that occur when anthracycline and paclitaxel are administered together might result in subadditive antitumor activity, a phase III study is comparing concomitant vs sequential administration of epirubicin and paclitaxel in patients with advanced breast cancer. A phase I/II study of epirubicin plus docetaxel as first-line chemotherapy for advanced breast cancer patients evaluated the maximum tolerated doses and for subsequent studies recommended epirubicin at 75 mg/m2 plus docetaxel at 80 mg/m2. In the adjuvant setting, an ongoing phase III trial is comparing epirubicin plus paclitaxel vs FEC (fluorouracil, epirubicin, and cyclophosphamide [Cytoxan, Neosar]) in node-positive patients. Preliminary data confirm the cardiac safety of these treatments.

Original languageEnglish
Pages (from-to)21-23
Number of pages3
JournalOncology
Volume15
Issue number5 SUPPL. 7
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Epirubicin/taxane combinations in breast cancer: Experience from several Italian trials'. Together they form a unique fingerprint.

  • Cite this

    Conte, P., Gennari, A., Guarneri, V., Landucci, E., Donati, S., Salvadori, B., Bengala, C., Orlandini, C., & Baldini, E. (2001). Epirubicin/taxane combinations in breast cancer: Experience from several Italian trials. Oncology, 15(5 SUPPL. 7), 21-23.